1 week EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates Zacks

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -56.10% and 21.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?